Thomas Broggini1, Marcus Czabanka2, Andras Piffko1, Christoph Harms3, Christian Hoffmann3, Ralf Mrowka4, Frank Wenke4, Urban Deutsch5, Carsten Grötzinger6, Peter Vajkoczy1. 1. Department of Neurosurgery, Universitätsmedizin Charite, Augustenburger Platz 1, 13353, Berlin, Germany. 2. Department of Neurosurgery, Universitätsmedizin Charite, Augustenburger Platz 1, 13353, Berlin, Germany. marcus.czabanka@charite.de. 3. Department of Experimental Neurology, Universitätsmedizin Charite, Berlin, Germany. 4. Experimental Nephrology, Universitätsklinikum, Jena, Germany. 5. Theodor Kocher Institute, University of Berne, Berne, Germany. 6. Department for Hepatology and Gastroenterology, Charite, Berlin, Germany.
Abstract
INTRODUCTION: Clinical treatment of spinal metastasis is gaining in complexity while the underlying biology remains unknown. Insufficient biological understanding is due to a lack of suitable experimental animal models. Intercellular adhesion molecule-1 (ICAM1) has been implicated in metastasis formation. Its role in spinal metastasis remains unclear. It was the aim to generate a reliable spinal metastasis model in mice and to investigate metastasis formation under ICAM1 depletion. MATERIAL AND METHODS: B16 melanoma cells were infected with a lentivirus containing firefly luciferase (B16-luc). Stable cell clones (B16-luc) were injected retrogradely into the distal aortic arch. Spinal metastasis formation was monitored using in vivo bioluminescence imaging/MRI. Neurological deficits were monitored daily. In vivo selected, metastasized tumor cells were isolated (mB16-luc) and reinjected intraarterially. mB16-luc cells were injected intraarterially in ICAM1 KO mice. Metastasis distribution was analyzed using organ-specific fluorescence analysis. RESULTS: Intraarterial injection of B16-luc and metastatic mB16-luc reliably induced spinal metastasis formation with neurological deficits (B16-luc:26.5, mB16-luc:21 days, p<0.05). In vivo selection increased the metastatic aggressiveness and led to a bone specific homing phenotype. Thus, mB16-luc cells demonstrated higher number (B16-luc: 1.2±0.447, mB16-luc:3.2±1.643) and increased total metastasis volume (B16-luc:2.87±2.453 mm3, mB16-luc:11.19±3.898 mm3, p<0.05) in the spine. ICAM1 depletion leads to a significantly reduced number of spinal metastasis (mB16-luc:1.2±0.84) with improved neurological outcome (29 days). General metastatic burden was significantly reduced under ICAM1 depletion (control: 3.47×10(7)±1.66×10(7); ICAM-1-/-: 5.20×10(4)±4.44×10(4), p<0.05 vs. control) CONCLUSION: Applying a reliable animal model for spinal metastasis, ICAM1 depletion reduces spinal metastasis formation due to an organ-unspecific reduction of metastasis development.
INTRODUCTION: Clinical treatment of spinal metastasis is gaining in complexity while the underlying biology remains unknown. Insufficient biological understanding is due to a lack of suitable experimental animal models. Intercellular adhesion molecule-1 (ICAM1) has been implicated in metastasis formation. Its role in spinal metastasis remains unclear. It was the aim to generate a reliable spinal metastasis model in mice and to investigate metastasis formation under ICAM1 depletion. MATERIAL AND METHODS: B16 melanoma cells were infected with a lentivirus containing firefly luciferase (B16-luc). Stable cell clones (B16-luc) were injected retrogradely into the distal aortic arch. Spinal metastasis formation was monitored using in vivo bioluminescence imaging/MRI. Neurological deficits were monitored daily. In vivo selected, metastasized tumor cells were isolated (mB16-luc) and reinjected intraarterially. mB16-luc cells were injected intraarterially in ICAM1 KO mice. Metastasis distribution was analyzed using organ-specific fluorescence analysis. RESULTS: Intraarterial injection of B16-luc and metastatic mB16-luc reliably induced spinal metastasis formation with neurological deficits (B16-luc:26.5, mB16-luc:21 days, p<0.05). In vivo selection increased the metastatic aggressiveness and led to a bone specific homing phenotype. Thus, mB16-luc cells demonstrated higher number (B16-luc: 1.2±0.447, mB16-luc:3.2±1.643) and increased total metastasis volume (B16-luc:2.87±2.453 mm3, mB16-luc:11.19±3.898 mm3, p<0.05) in the spine. ICAM1 depletion leads to a significantly reduced number of spinal metastasis (mB16-luc:1.2±0.84) with improved neurological outcome (29 days). General metastatic burden was significantly reduced under ICAM1 depletion (control: 3.47×10(7)±1.66×10(7); ICAM-1-/-: 5.20×10(4)±4.44×10(4), p<0.05 vs. control) CONCLUSION: Applying a reliable animal model for spinal metastasis, ICAM1 depletion reduces spinal metastasis formation due to an organ-unspecific reduction of metastasis development.
Authors: Timothy C Ryken; Kurt M Eichholz; Peter C Gerszten; William C Welch; Ziya L Gokaslan; Daniel K Resnick Journal: Neurosurg Focus Date: 2003-11-15 Impact factor: 4.047
Authors: Tanjew Dittgen; Axel Nimmerjahn; Shoji Komai; Pawel Licznerski; Jack Waters; Troy W Margrie; Fritjof Helmchen; Winfried Denk; Michael Brecht; Pavel Osten Journal: Proc Natl Acad Sci U S A Date: 2004-12-17 Impact factor: 11.205
Authors: Mélanie Héroult; Florence Schaffner; Dennis Pfaff; Claudia Prahst; Robert Kirmse; Simone Kutschera; Maria Riedel; Thomas Ludwig; Peter Vajkoczy; Ralph Graeser; Hellmut G Augustin Journal: Mol Cancer Res Date: 2010-09-13 Impact factor: 5.852
Authors: Caridad Rosette; Richard B Roth; Paul Oeth; Andreas Braun; Stefan Kammerer; Jonas Ekblom; Mikhail F Denissenko Journal: Carcinogenesis Date: 2005-03-17 Impact factor: 4.944
Authors: Nils Hecht; Jin He; Irina Kremenetskaia; Melina Nieminen; Peter Vajkoczy; Johannes Woitzik Journal: Stroke Date: 2012-08-23 Impact factor: 7.914
Authors: Thomas Broggini; Andras Piffko; Christian J Hoffmann; Christoph Harms; Peter Vajkoczy; Marcus Czabanka Journal: PLoS One Date: 2016-09-07 Impact factor: 3.240
Authors: Alison L Halpern; Patrick D Kohtz; Jessica Y Rove; Lihua Ao; Xianzhong Meng; David A Fullerton; Michael J Weyant Journal: Mol Cell Biochem Date: 2019-01-25 Impact factor: 3.396